SS. Patel, AJ. Wagstaff, A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection., in Drugs, vol. 52, n. 2, Ago 1996, pp. 254-75, PMID 8841742.
A. Podda, L. Nencioni; MT. De Magistris; A. Di Tommaso; P. Bossù; S. Nuti; P. Pileri; S. Peppoloni; M. Bugnoli; P. Ruggiero, Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G., in J Exp Med, vol. 172, n. 3, Set 1990, pp. 861-8, PMID 2201750.
L. Nencioni, G. Volpini; S. Peppoloni; M. Bugnoli; T. De Magistris; I. Marsili; R. Rappuoli, Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment., in Infect Immun, vol. 59, n. 2, Feb 1991, pp. 625-30, PMID 1702767.
Cowan LD, Griffin MR, Howson CP, Katz M, Johnston RB Jr, Shaywitz BA, Fineberg HV., Acute encephalopathy and chronic neurological damage after pertussis vaccine., in Vaccine, 11(14), Nov 1993, pp. 1371-9, PMID7906066.
CF. von Reyn, CJ. Clements; JM. Mann, Human immunodeficiency virus infection and routine childhood immunisation., in Lancet, vol. 2, n. 8560, Set 1987, pp. 669-72, PMID 2887950.
F. Dabis, P. Lepage; P. Msellati; P. Van de Perre; F. Nsengumuremyi; DG. Hitimana; J. Ladner; V. Leroy, [Routine vaccinations in children and adults infected with HIV]., in Sante, vol. 4, n. 3, pp. 173-82, PMID 7921682.
